Associations - imatinib

KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
No biomarker	Fibrosarcoma	No biomarker	Fibrosarcoma	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
KIT expression	Gastrointestinal Stromal Tumor	KIT expression	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
PDGFRA rearrangement	Myelodysplastic Syndrome	PDGFRA rearrangement	Myelodysplastic Syndrome	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	imatinib Resistant: A2 - Guideline imatinib Resistant : A2	imatinib Resistant: A2 - Guideline imatinib Resistant : A2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
PDGFRA D842V	Gastric Cancer	PDGFRA D842V	Gastric Cancer	imatinib Resistant: A2 - Guideline imatinib Resistant : A2	imatinib Resistant: A2 - Guideline imatinib Resistant : A2
No biomarker	Chordoma	No biomarker	Chordoma	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
KIT mutation	Cutaneous Melanoma	KIT mutation	Cutaneous Melanoma	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
KIT exon 11 mutation	Gastric Cancer	KIT exon 11 mutation	Gastric Cancer	imatinib Sensitive: B - Late Trials imatinib Sensitive : B	imatinib Sensitive: B - Late Trials imatinib Sensitive : B
KIT exon 9 mutation	Gastric Cancer	KIT exon 9 mutation	Gastric Cancer	imatinib Resistant: B - Late Trials imatinib Resistant : B	imatinib Resistant: B - Late Trials imatinib Resistant : B
PDGFRA mutation	Gastric Cancer	PDGFRA mutation	Gastric Cancer	imatinib Sensitive: B - Late Trials imatinib Sensitive : B	imatinib Sensitive: B - Late Trials imatinib Sensitive : B
KIT exon 13 mutation	Melanoma	KIT exon 13 mutation	Melanoma	imatinib Sensitive: B - Late Trials imatinib Sensitive : B	imatinib Sensitive: B - Late Trials imatinib Sensitive : B
KIT expression	Endometrial Cancer	KIT expression	Endometrial Cancer	imatinib Sensitive: C1 - Off-label imatinib Sensitive : C1	imatinib Sensitive: C1 - Off-label imatinib Sensitive : C1
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3
miR-146a expression	Chronic Myeloid Leukemia	miR-146a expression	Chronic Myeloid Leukemia	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
KIT K642E	Melanoma	KIT K642E	Melanoma	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
BCR-ABL1 Q252H	Chronic Myeloid Leukemia	BCR-ABL1 Q252H	Chronic Myeloid Leukemia	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3
BCR-ABL1 M351T	Chronic Myeloid Leukemia	BCR-ABL1 M351T	Chronic Myeloid Leukemia	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3
BCR-ABL1 L248V	Chronic Myeloid Leukemia	BCR-ABL1 L248V	Chronic Myeloid Leukemia	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3
BCR-ABL1 F359V	Chronic Myeloid Leukemia	BCR-ABL1 F359V	Chronic Myeloid Leukemia	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3

imatinib

Associations
(166)

Associations
(166)

imatinib

Associations(166)

Associations(166)

Associations
(166)

Associations
(166)